In starved antibiotic field, Melinta soars as FDA grants speedy drug review

In starved antibiotic field, Melinta soars as FDA grants speedy drug review

Source: 
Endpoints
snippet: 

On Wednesday, Melinta Therapeutics said its approved antibiotic Baxdela had been granted priority review for use in community-acquired bacterial pneumonia (CAPB). The FDA is expected to make its decision by October 24.